We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

An AI-enabled multi-biomarker blood test detects early-stage pancreatic cancer (87% sensitivity) and flags high-grade dysplasia. More...
16 Sep 2026
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

A nanoparticle-based blood test detects amoxicillin/penicillin allergy with 98% sensitivity. More...
16 Sep 2026
Image Credit: Diane E. MacDougall et al., FIND Lp(a) Machine Learning Model: Targeted Screening Enrichment of Elevated Lipoprotein(a) in Atherosclerotic Cardiovascular Disease, JACC: Advances (2026). DOI: 10.1016/j.jacadv.2026.103114

Machine Learning Supports Targeted Screening for Elevated Lipoprotein(a)

An AI approach leverages EMR data to target Lp(a) screening, finding ASCVD patients over 2x likelier to have high levels. More...
16 Sep 2026
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte has acquired Convergent Genomics, adding its UroAmp urinary tumor DNA platform to its urology diagnostics portfolio. More...
16 Sep 2026
Image: Researchers from Korea University investigated whether changes in plasma p-tau217 could provide an early, minimally invasive measure of biological response to lecanemab in people with early Alzheimer’s disease (Image Credit: Prof. Sung Hoon Kang from Korea University College of Medicine)

Blood Biomarker May Help Monitor Early Response to Lecanemab in Alzheimer’s Disease

A blood-based p-tau217 test tracks early response to lecanemab and aligns with slower cognitive decline in early AD. More...
16 Sep 2026
Image: Concentriq AP-Dx supports primary diagnosis from digital pathology slides and is FDA-cleared, Health Canada-licensed, and CE-marked under the EU IVDR. (Photo courtesy of Proscia)

Unilabs Expands Digital Pathology Across European Network with Proscia Platform

Proscia announced that Unilabs is leveraging the Concentriq platform to advance digital pathology across its European network More...
16 Sep 2026
Image: Under the theme “From Tissue to Answer”, the launch of VisiOmics anchors a comprehensive pathology portfolio spanning tissue and molecular pathology (Photo courtesy of MGI Tech Co., Ltd.)

MGI Launches Automated Multiplex Tissue Staining and Imaging System at ECP 2026

MGI Tech introduced VisiOmics (PMIF-20RS), a fully automated multiplex immunofluorescence staining and imaging system, at ECP 2026 in Stockholm. More...
16 Sep 2026
Visit expo >
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test

In Other News

Copyright © 2000 - 2026 Globetech Media.
All rights reserved.